BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 12040468)

  • 1. Stem cell mobilisation with 16 microg/kg vs 10 microg/kg of G-CSF for allogeneic transplantation in healthy donors.
    Kröger N; Renges H; Sonnenberg S; Krüger W; Gutensohn K; Dielschneider T; Cortes-Dericks L; Zander AR
    Bone Marrow Transplant; 2002 May; 29(9):727-30. PubMed ID: 12040468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation.
    Kröger N; Renges H; Krüger W; Gutensohn K; Löliger C; Carrero I; Cortes L; Zander AR
    Br J Haematol; 2000 Dec; 111(3):761-5. PubMed ID: 11122135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors.
    Martínez C; Urbano-Ispizua A; Marín P; Merino A; Rovira M; Carreras E; Montserrat E
    Bone Marrow Transplant; 1999 Dec; 24(12):1273-8. PubMed ID: 10627634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation.
    Sohn SK; Kim JG; Seo KW; Chae YS; Jung JT; Suh JS; Lee KB
    Bone Marrow Transplant; 2002 Jul; 30(2):81-6. PubMed ID: 12132046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised study of 10 microg/kg/day (single dose) vs 2 x 5 microg/kg/day (split dose) G-CSF as stem cell mobilisation regimen in high-risk breast cancer patients.
    Carrión R; Serrano D; Gómez-Pineda A; Díez-Martín JL
    Bone Marrow Transplant; 2003 Sep; 32(6):563-7. PubMed ID: 12953127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg).
    Kröger N; Zeller W; Hassan HT; Krüger W; Gutensohn K; Löliger C; Zander AR
    Bone Marrow Transplant; 1999 Jan; 23(2):125-9. PubMed ID: 10197796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Collection of hematopoietic progenitor cells from healthy donors].
    Bojanić I; Cepulić BG; Mazić S
    Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single vs twice daily G-CSF dose for peripheral blood stem cells harvest in normal donors and children with non-malignant diseases.
    Lee V; Li CK; Shing MM; Chik KW; Li K; Tsang KS; Zhao DC; Lai DH; Wong A; Yuen PM
    Bone Marrow Transplant; 2000 May; 25(9):931-5. PubMed ID: 10800059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors.
    Fischer JC; Frick M; Wassmuth R; Platz A; Punzel M; Wernet P
    Br J Haematol; 2005 Sep; 130(5):740-6. PubMed ID: 16115131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantation.
    Arbona C; Prosper F; Benet I; Mena F; Solano C; Garcia-Conde J
    Bone Marrow Transplant; 1998 Jul; 22(1):39-45. PubMed ID: 9678794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone.
    Devine SM; Brown RA; Mathews V; Trinkaus K; Khoury H; Adkins D; Vij R; Sempek D; Graubert T; Tomasson M; Goodnough LT; DiPersio JF
    Bone Marrow Transplant; 2005 Sep; 36(6):531-8. PubMed ID: 16025152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection.
    Engelhardt M; Bertz H; Afting M; Waller CF; Finke J
    J Clin Oncol; 1999 Jul; 17(7):2160-72. PubMed ID: 10561272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors.
    Kroschinsky F; Hölig K; Poppe-Thiede K; Zimmer K; Ordemann R; Blechschmidt M; Oelschlaegel U; Bornhauser M; Rall G; Rutt C; Ehninger G
    Haematologica; 2005 Dec; 90(12):1665-71. PubMed ID: 16330441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used.
    Ings SJ; Balsa C; Leverett D; Mackinnon S; Linch DC; Watts MJ
    Br J Haematol; 2006 Sep; 134(5):517-25. PubMed ID: 17018030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors.
    Suzuya H; Watanabe T; Nakagawa R; Watanabe H; Okamoto Y; Onishi T; Abe T; Kawano Y; Kagami S; Takaue Y
    Vox Sang; 2005 Nov; 89(4):229-35. PubMed ID: 16262756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
    Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
    Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis.
    Snowden JA; Biggs JC; Milliken ST; Fuller A; Staniforth D; Passuello F; Renwick J; Brooks PM
    Bone Marrow Transplant; 1998 Dec; 22(11):1035-41. PubMed ID: 9877264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
    Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
    Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.